4P-021 is under clinical development by 4P-Pharma and currently in Phase II for Acute Respiratory Distress Syndrome. According to GlobalData, Phase II drugs for Acute Respiratory Distress Syndrome have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how 4P-021’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Plerixafor is under development for the treatment of acute respiratory distress syndrome and pulmonary complications. The drug candidate is a repurposed formulation and is administered by intravenous route. It acts by targeting C-X-C chemokine receptor type 4 (CXCR-4).
4P-Pharma is a clinical-stage biotechnology company that focuses on high unmet medical needs in the treatment of untreated serious diseases. The company, after reaching regulatory milestones, launches single product vehicle (SPV) companies to advance the pipeline compounds through clinical development to market approval and distribution agreements by therapeutic and geographic areas. It established two clinical-stage SPV companies, 4Moving Biotech, and 4Living Biotech. 4Moving Biotech is developing 4P004, a disease-modifying drug candidate for osteoarthritis, and 4Living Biotech is developing 4P021, a drug candidate for the curative treatment of chronic and acute pulmonary complications due to infection. The company is also developing 4P020 for Stargardt disease and macular degeneration; 4P022 for systemic sclerosis, and 4P025 for liver diseases. 4P Pharma is headquartered in Lille, France.
For a complete picture of 4P-021’s drug-specific PTSR and LoA scores, buy the report here.